Search

Author/Creator Luo, Yunting

1. Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition. Issue 1 (23rd November 2017)

Authors:
Phadke, Manali; Remsing Rix, Lily L.; Smalley, Inna; Bryant, Annamarie T.; Luo, Yunting; Lawrence, Harshani R.; Schaible, Braydon J.; Chen, Yian A.; Rix, Uwe; Smalley, Keiran S. M.
Journal:
Molecular oncology
Issue:
Volume 12:Issue 1(2018)
Page Start:
74
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Issue 12 (22nd December 2016)

Authors:
Knezevic, Claire E.; Wright, Gabriela; Remsing Rix, Lily L.; Kim, Woosuk; Kuenzi, Brent M.; Luo, Yunting; Watters, January M.; Koomen, John M.; Haura, Eric B.; Monteiro, Alvaro N.; Radu, Caius; Lawrence, Harshani R.; Rix, Uwe
Journal:
Cell chemical biology
Issue:
Volume 23:Issue 12(2016)
Page Start:
1490
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Issue 2 (17th February 2022)

Authors:
Palve, Vinayak; Knezevic, Claire E.; Bejan, Daniel S.; Luo, Yunting; Li, Xueli; Novakova, Silvia; Welsh, Eric A.; Fang, Bin; Kinose, Fumi; Haura, Eric B.; Monteiro, Alvaro N.; Koomen, John M.; Cohen, Michael S.; Lawrence, Harshani R.; Rix, Uwe
Journal:
Cell chemical biology
Issue:
Volume 29:Issue 2(2022)
Page Start:
202
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗